Identification of Small Molecule Inhibitors of Human Cytomegalovirus pUL89 Endonuclease Using Integrated Computational Approaches

Replication of Human Cytomegalovirus (HCMV) requires the presence of a metal-dependent endonuclease at the C-terminus of pUL89, in order to properly pack and cleave the viral genome. Therefore, pUL89 is an attractive target to design anti-CMV intervention. Herein, we used integrated structure-based and ligand-based virtual screening approaches in combination with MD simulation for the identification of potential metal binding small molecule antagonist of pUL89. In this regard, the essential chemical features needed for the inhibition of pUL89 endonuclease domain were defined and used as a 3D query to search chemical compounds from ZINC and ChEMBL database. Thereafter, the molecular docking and ligand-based shape screening were used to narrow down the compounds based on previously identified pUL89 antagonists. The selected virtual hits were further subjected to MD simulation to determine the intrinsic and ligand-induced flexibility of pUL89. The predicted binding modes showed that the compounds reside well in the binding site of endonuclease domain by chelating with the metal ions and crucial residues. Taken in concert, the in silico investigation led to the identification of potential pUL89 antagonists. This study provided promising starting point for further in vitro and in vivo studies.

[1]  Jiashu Xie,et al.  Repurposing N-hydroxy thienopyrimidine-2,4-diones (HtPD) as inhibitors of human cytomegalovirus pUL89 endonuclease: Synthesis and biological characterization. , 2022, Bioorganic chemistry.

[2]  S. Khan,et al.  Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein , 2022, International journal of molecular sciences.

[3]  R. Geraghty,et al.  8‐Hydroxy‐1,6‐naphthyridine‐7‐carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease , 2022, ChemMedChem.

[4]  Jiashu Xie,et al.  4,5-Dihydroxypyrimidine Methyl Carboxylates, Carboxylic Acids, and Carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease. , 2022, Journal of medicinal chemistry.

[5]  D. Kimberlin,et al.  Cytomegalovirus variation among newborns treated with valganciclovir. , 2022, Antiviral research.

[6]  M. Mozafarybazargany,et al.  Severe cytomegalovirus encephalitis in an immunocompetent healthy young woman: A case report , 2022, IDCases.

[7]  H. Patel,et al.  Encephalitis Due to Co-Infection with Cytomegalovirus and Herpes Simplex Virus Type 2 in a Patient with Acquired Immunodeficiency Syndrome , 2021, The American journal of case reports.

[8]  Yan Wang,et al.  Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus (HCMV) , 2021, Acta pharmaceutica Sinica. B.

[9]  Jiashu Xie,et al.  Metal binding 6-arylthio-3-hydroxypyrimidine-2,4-diones inhibited human cytomegalovirus by targeting the pUL89 endonuclease of the terminase complex. , 2021, European journal of medicinal chemistry.

[10]  Halli E. Miller,et al.  Inhibition of Human Coronaviruses by Antimalarial Peroxides , 2021, ACS infectious diseases.

[11]  A. Loregian,et al.  The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs. , 2021, Antiviral research.

[12]  S. Khan,et al.  Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease , 2021, Journal of Molecular Structure.

[13]  C. Crumpacker,et al.  Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection , 2020, The Journal of infectious diseases.

[14]  Reaz Uddin,et al.  Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach , 2020, Journal of biomolecular structure & dynamics.

[15]  D. Wolf,et al.  Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. , 2019, Antiviral research.

[16]  R. Razonable,et al.  Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation , 2019, Expert opinion on drug safety.

[17]  R. Kaiser,et al.  Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency , 2019, Open forum infectious diseases.

[18]  P. Griffiths,et al.  Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysis , 2019, Reviews in medical virology.

[19]  F. Albericio,et al.  Structure-Driven Discovery of α,γ-Diketoacid Inhibitors Against UL89 Herpesvirus Terminase , 2018, ACS omega.

[20]  Yan Wang,et al.  Hydroxypyridonecarboxylic Acids as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease , 2018, ChemMedChem.

[21]  Yan Wang,et al.  Metal‐chelating 3‐hydroxypyrimidine‐2,4‐diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication , 2018, Antiviral research.

[22]  S Alain,et al.  The human cytomegalovirus terminase complex as an antiviral target: a close-up view , 2018, FEMS microbiology reviews.

[23]  M. Messerle,et al.  Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation , 2017, Journal of Virology.

[24]  D. Brennan,et al.  Letermovir for the management of cytomegalovirus infection , 2017, Expert opinion on investigational drugs.

[25]  Yan Wang,et al.  Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage , 2016, Journal of Virology.

[26]  P. Moss,et al.  Sociodemographic factors associated with IgG and IgM seroprevalence for human cytomegalovirus infection in adult populations of Pakistan: a seroprevalence survey , 2016, BMC Public Health.

[27]  Rajendra Kumar,et al.  g_mmpbsa - A GROMACS Tool for High-Throughput MM-PBSA Calculations , 2014, J. Chem. Inf. Model..

[28]  M. Michaels,et al.  Ganciclovir, Foscarnet, and Cidofovir: Antiviral Drugs Not Just for Cytomegalovirus. , 2013, Journal of the Pediatric Infectious Diseases Society.

[29]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[30]  Fredrik Svensson,et al.  Virtual Screening Data Fusion Using Both Structure- and Ligand-Based Methods , 2012, J. Chem. Inf. Model..

[31]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[32]  P. Mas,et al.  Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain , 2010, Proceedings of the National Academy of Sciences.

[33]  Dennis M. Krüger,et al.  Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.

[34]  Hanna Geppert,et al.  Integrating Structure‐ and Ligand‐Based Virtual Screening: Comparison of Individual, Parallel, and Fused Molecular Docking and Similarity Search Calculations on Multiple Targets , 2008, ChemMedChem.

[35]  A. Loregian,et al.  Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. , 2006, Chemistry & biology.

[36]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[37]  R. Rigatti,et al.  Inhibition of Human Cytomegalovirus DNA Polymerase by C-Terminal Peptides from the UL54 Subunit , 2003, Journal of Virology.

[38]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[39]  Human Cytomegaloviruses: Methods and Protocols , 2021 .

[40]  G. Boivin,et al.  Antiviral Drugs Against Herpesviruses. , 2021, Advances in experimental medicine and biology.

[41]  A. Yurochko,et al.  Overview of human cytomegalovirus pathogenesis. , 2014, Methods in molecular biology.

[42]  D. Burger Antiviral drug discovery and development , 2007, Nature reviews. Drug discovery.